The National Health Institute said the results of two blood serum studies from people who had received Covaxin showed that vaccines produce antibodies that effectively neutralize B.1.1.7 and B.617 SARS-COV-2 variants.
India Covaxin, developed by Bharat Biotech in collaboration with the Indian Medical Research Council, effectively neutralized the Alpha and Delta variants from Coronavirus, said the US National Institute of Health.
Here says the results of two blood serum studies from people who have received Covaxin show that vaccines produce antibodies that effectively neutralize B.1.1.7 (Alpha) and B1.617 (Delta) variant SARS-COV-2, first identified in the UK and India, respectively.
The top American Health Research Institute, which has a strong scientific collaboration history with India, also said that the adjuvant developed with funds from IT has contributed to the success of the efficacious Covaxin, which has been given around 25 million people to date in India and elsewhere ,
